Mohamed Aia, Rogers Thomas R, Talento Alida Fe
Department of Microbiology, Our Lady of Lourdes Hospital Drogheda, A92 VW28 Co. Louth, Ireland.
Department of Clinical Microbiology, Trinity College Dublin, St. James's Hospital Campus, D08 NHY1 Dublin, Ireland.
J Fungi (Basel). 2020 Jul 22;6(3):115. doi: 10.3390/jof6030115.
co-infection in patients with severe coronavirus disease 2019 (COVID-19) pneumonia, leading to acute respiratory distress syndrome, has recently been reported. To date, 38 cases have been reported, with other cases most likely undiagnosed mainly due to a lack of clinical awareness and diagnostic screening. Importantly, there is currently no agreed case definition of COVID-19 associated invasive pulmonary aspergillosis (CAPA) that could aid in the early detection of this co-infection. Additionally, with the global emergence of triazole resistance, we emphasize the importance of antifungal susceptibility testing in order to ensure appropriate antifungal therapy. Herein is a review of 38 published CAPA cases, which highlights the diagnostic and therapeutic challenges posed by this novel fungal co-infection.
近期有报道称，2019冠状病毒病（COVID-19）重症肺炎患者出现合并感染，导致急性呼吸窘迫综合征。截至目前，已报告38例病例，其他病例很可能因缺乏临床认识和诊断筛查而未被诊断出来。重要的是，目前尚无公认的COVID-19相关侵袭性肺曲霉病（CAPA）病例定义，这可能有助于早期发现这种合并感染。此外，随着全球三唑耐药性的出现，我们强调抗真菌药敏试验的重要性，以确保进行适当的抗真菌治疗。本文对38例已发表的CAPA病例进行了综述，突出了这种新型真菌合并感染所带来的诊断和治疗挑战。
